Our 2030 estimates contemplate global penetration into the addressable type 2 diabetes and obesity markets of only 8% and 2%, respectively (from about 3% and 0.2% in 2023). Uptake would likely be greater if these drugs could be consumed in oral form rather than injected, adds the report, An oral weight loss agent would likely be well-received in the primary care setting and could alleviate pressure on supply chains
3 Under long-standing federal rules, medications used for anorexia, weight loss, or weight gain, are specifically excluded from the definition of Part D drugs . 4 But glucagon-like peptide-1 (GLP-1) receptor agonists such as Ozempic and Mounjaro can be covered by Medicare Part D if theyre prescribed for other medical conditions
Approved by the FDA for type 2 diabetes management (as Ozempic and Rybelsus) and chronic weight management (as Wegovy), semaglutide represents a significant advancement in GLP-1-based therapeutics
The consensus rating on LLY shares sits at Strong Buy currently, with the mean price target of 1,232 indicating potential upside of more than 30% from current levels
Read More GLP-1 Patches vs Oral GLP-1 Support Based on current evidence, oral GLP-1 support has a much stronger scientific foundation
"Individual patient eligibility for drug therapies available through Sesame are determined by the assessment of appropriateness of each therapy by the Sesame-listed provider, and are subject to availability," said the company